Cas:18299-15-5 4-(hydroxymethyl)-2-methylphenol manufacturer & supplier

We serve Chemical Name:4-(hydroxymethyl)-2-methylphenol CAS:18299-15-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-(hydroxymethyl)-2-methylphenol

Chemical Name:4-(hydroxymethyl)-2-methylphenol
CAS.NO:18299-15-5
Synonyms:2-methyl-4-hydroxymethylphenol;4-Hydroxy-3-methyl-1-hydroxymethyl-benzol;4-HYDROXY-3-METHYLBENZYL ALCOHOL;Benzenemethanol,4-hydroxy-3-methyl;4-Hydroxy-3-methyl-benzylalkohol
Molecular Formula:C8H10O2
Molecular Weight:138.16400
HS Code:2907299090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:40.46000
Exact Mass:138.06800
LogP:1.19290

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-methyl-4-hydroxymethylphenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Hydroxy-3-methyl-benzylalkohol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzenemethanol,4-hydroxy-3-methyl Use and application,Benzenemethanol,4-hydroxy-3-methyl technical grade,usp/ep/jp grade.


Related News: With the continuous accumulation of the API industry and the increasing maturity of the market, competition in China’s API industry will become increasingly fierce. 4-(hydroxymethyl)-2-methylphenol manufacturer The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 4-(hydroxymethyl)-2-methylphenol supplier Also, the study did not compare people who had COVID-19 with those who did not, to see if such symptoms were higher than in the general population. The report did exclude patients with certain serious or chronic preexisting conditions like cancer, kidney disease, HIV, liver disease and stroke, to separate their previous health status from post-COVID symptoms. 4-(hydroxymethyl)-2-methylphenol vendor With the continuous accumulation of the API industry and the increasing maturity of the market, competition in China’s API industry will become increasingly fierce. 4-(hydroxymethyl)-2-methylphenol factory Also, the study did not compare people who had COVID-19 with those who did not, to see if such symptoms were higher than in the general population. The report did exclude patients with certain serious or chronic preexisting conditions like cancer, kidney disease, HIV, liver disease and stroke, to separate their previous health status from post-COVID symptoms.